 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio nasal spray in...

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Altamira Therapeutics reports 1H of 2023 revenue CHF 0.1M vs CHF0.3M last year

HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical...

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript...

Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting...

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global  Investment Conference September 11-13

HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...

Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia

HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy-Study demonstrates statistically significant alleviation of nasal symptoms of allergic rhinitis Altamira Therapeutics Ltd. ("Altamira" or the "Company") (...

Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal

Altamira Therapeutics Ltd (NASDAQ: CYTO)shares are trading lower by 19.23% to $0.44 Thursday morning after the company announced pricing of a $5 million public offer
read more...

Why Altamira Therapeutics (CYTO) Stock Is Getting Hammered

Altamira Therapeutics prices ~$5M public offering of shares

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Watchers	25,719
52-Wk Low	$0.22
52-Wk High	$13.52

Market Cap	$2.16M
Volume (M)	642.00
52-Wk High	$13.52
52-Wk Low	$0.22

Current Price	$0.2445
Prev Close	$0.235
Open	$0.245
Dividend Yield	0.00%
50-Day Moving Average	$0.3339
Beta	1.13
Avg. Volume	98,673.00
PE Ratio	-0.01

52-Week High	$13.52
52-Week Low	$0.22
Market Capitalization	$2.16M
EPS	N/A
Price to Book	-0.95
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

CYTO Altamira Therapeutics Ltd

About

Feed

News

Earnings

Fundamentals